论文部分内容阅读
目的评价不同途经氨溴索针剂辅助治疗小儿肺炎的临床疗效及安全性。方法将同期住院的300例肺炎患儿随机分为治疗组与对照组,每组150例。治疗组除按所感染病原的不同常规给予合理的抗感染,对症支持治疗外,均辅助氨溴索治疗,其中治疗组再随机分为氨溴索氧气驱动雾化吸入组(A组),氨溴索静脉滴注组(B组),联合应用氨溴索针剂雾化吸入及氨溴索静脉滴注组(C组);对照组仅按常规方法根据感染病原的不同给予抗感染,对症支持治疗。临床观察患儿体温恢复正常时间、咳嗽气促,喉中痰鸣缓解和肺部啰音吸收等好转情况及可能的药物不良反应,并进行住院天数比较。结果治疗组中除A、B两组患儿体温恢复正常时间与对照组无显著差异外,咳嗽消失时间,喉中痰鸣缓解,肺部啰音吸收等好转情况均优于对照组,住院天数较对照组缩短,经统计学处理,两者差异有统计学意义(P<0.05);尤其C组效果更明显(P<0.01),且临床上未发现任何明显不良反应。A、B、C 3个治疗组的总有效率均比对照组明显提高,但各治疗组之间临床疗效比较,差异并无统计学意义(P<0.05)。结论多种途径使用氨溴索针剂辅助治疗小儿肺炎均有较好疗效,联合使用氨溴索雾化吸入及静脉滴注治疗效果更显著,且安全。
Objective To evaluate the clinical efficacy and safety of different routes of ambroxol adjuvant therapy for children with pneumonia. Methods 300 cases of pneumonia patients hospitalized in the same period were randomly divided into treatment group and control group, with 150 cases in each group. The treatment group was treated with ambroxol in addition to the conventional anti-infection and symptomatic supportive therapy according to the different routine of the infected pathogen. The treatment group was randomly divided into ambroxol oxygen inhalation group (group A), ammonia The patients in group B received intravenous injection of ambroxol and intravenous infusion of ambroxol (group C). The control group received anti-infective and symptomatic support only according to the conventional method according to the different pathogens treatment. Clinical observation of children with normal body temperature recovery, cough and shortness of breath, throat phlegm and lung auscultation and other improvement of the situation and possible adverse drug reactions, and the number of hospital days comparison. Results The treatment group except A, B two groups of children with normal body temperature recovery time was no significant difference with the control group, the cough disappear time, the throat sputum remission, pulmonary rales and other improvements were better than the control group, hospitalization days Compared with the control group, the difference between the two groups was statistically significant (P <0.05), especially in group C (P <0.01). No obvious adverse reactions were found clinically. The total effective rate of A, B and C treatment groups was significantly higher than that of control group, but there was no significant difference between the treatment groups in clinical efficacy (P <0.05). Conclusions Ambroxol is an effective adjunctive therapy for children with pneumonia, and the combination of ambroxol inhalation and intravenous drip is more effective and safe.